Nolato AB (publ) (NOLA_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to today's presentation with Nolato. With us presenting today, we have the CEO, Christer Walkvist, and CFO, Per-Olo Holmström. If you're calling in and would like to ask a question, please press star 9 to raise your hand and star 6 to mute yourself when you get to work. You can also use the form located to the right. And with that said, please go ahead with your presentation. Okay, good morning everybody and welcome to the presentation of the second quarter for Nolato Group. Turning to page two in the presentation and the summary of Nolato Group. We had during this quarter sales that amounted to just shy of 2.4 billions, which then gives a currency adjusted organic growth of 4%. We saw growth in both business area. We saw growth a sharp increase of our EBIT A margin, increasing 1.6 percentage points to 11.6, and creating an increase of our operating profit by 13% to 277 millions, despite a strong currency headwind. Turning to page three. summarizing up the Nalato group and the two business areas. So the group is built up based on two distinct business areas, with the medical solution being the largest portion, and then engineered just close by in size. If we turn to page four, focusing on our medical solutions business areas, here you can see a graph of 20 years consecutive growth. And of course, we are focusing on continuous growth and global expansion with this business area. Turning to page five, summarizing up our focus products areas within medical solution, starting in vitro diagnostics. It's a high volume market with good growth potential going forward. Then we have our cardiology part with lifetime implants and very high demand products. Third, pharma packaging, which is consistent of containers for solid and liquid drugs. We have our...